Search research articles
Contact Us
Filters
Showing results (311-320 of 337) with videos related to
Page
of 34
Sort By:
Plos Pathogens
|
October 8, 2011
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections
S Gnanakaran, Tanmoy Bhattacharya, Marcus Daniels, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine
Youyi Fong, Yunda Huang, Ying Huang, et al.
Ebiomedicine
|
June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Kelly E Seaton, Yunda Huang, Shelly Karuna, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
The New England Journal of Medicine
|
March 17, 2021
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Lawrence Corey, Peter B Gilbert, Michal Juraska, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Nature Immunology
|
October 6, 2025
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
The Journal of Infectious Diseases
|
June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zoe Moodie, One Dintwe, Sheetal Sawant, et al.
Nature Communications
|
April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Youyi Fong, Lauren Dang, Bo Zhang, et al.
Page
of 34
Search research articles
Search
Showing results (311-320 of 337) with videos related to
Sort By:
Page
of 34
Plos Pathogens
|
October 8, 2011
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections
S Gnanakaran, Tanmoy Bhattacharya, Marcus Daniels, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine
Youyi Fong, Yunda Huang, Ying Huang, et al.
Ebiomedicine
|
June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Kelly E Seaton, Yunda Huang, Shelly Karuna, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
The New England Journal of Medicine
|
March 17, 2021
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Lawrence Corey, Peter B Gilbert, Michal Juraska, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Nature Immunology
|
October 6, 2025
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
The Journal of Infectious Diseases
|
June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zoe Moodie, One Dintwe, Sheetal Sawant, et al.
Nature Communications
|
April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Youyi Fong, Lauren Dang, Bo Zhang, et al.
Page
of 34